|Free Dividend Report|
|Stock Splits Calendar|
|ACRX Stock Split History|
|Preferred Stock Newsletter|
|ACRX Options Chain|
|ACRX Message Board|
AcelRx Pharmaceuticals (ACRX) has 1 split in our ACRX split history database. The split for ACRX took place on October 26, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of ACRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as AcelRx Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ACRX split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AcelRx Pharmaceuticals shares, starting with a $10,000 purchase of ACRX, presented on a split-history-adjusted basis factoring in the complete ACRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-40.64%|
|About AcelRx Pharmaceuticals|
|AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. Co.'s nafamostat product candidates include Niyad, which is being developed as a regional anticoagulant for injection into the extracorporeal circuit; and LTX-608, which is Co.'s proprietary nafamostat formulation for direct IV infusion. Co.'s pre-filled syringe product candidates include Fedsyra, which is an ephedrine pre-filled syringe; and the phenylephrine pre-filled syringe. According to our ACRX split history records, AcelRx Pharmaceuticals has had 1 split.|
|ACRX Split History Table|
|10/26/2022||1 for 20|
|Healthcare Stock Splits|
|ACRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
ACST Split History
Also explore: ACRX shares outstanding history
Free ACRX Email Alerts: